New Strong Buy Stocks for June 6th
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
These 3 Companies Boast Bright Outlooks
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Haemonetics (HAE) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
Best Momentum Stocks to Buy for May 28th
MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HAE or BSX: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Buy Haemonetics (HAE) Stock Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
